Intensity Therapeutics Reports Promising Clinical Data, Extends Cash Runway to 2027
Event summary
- Intensity Therapeutics reported $11.9M in cash as of December 31, 2025, with a runway into Q2 2027 after raising $20M in 2025.
- Preliminary INVINCIBLE-4 study data showed 71.4% pathological complete response (pCR) in TNBC patients treated with INT230-6 vs. 33% in the SOC arm.
- IT-01 study results published in eBioMedicine showed a 75% disease control rate and 11.9-month median overall survival in refractory metastatic cancer patients.
- The company resumed enrollment in the INVINCIBLE-4 study after receiving approval from Swissmedic and the Switzerland Ethics Committee.
The big picture
Intensity Therapeutics' latest data highlights the potential of its intratumoral approach to cancer treatment, which aims to kill tumors and stimulate immune responses without systemic toxicity. The company's ability to extend its cash runway into 2027 provides a buffer to advance its clinical programs, but securing additional funding will be critical to sustain momentum. The broader biotech sector continues to seek innovative cancer therapies, particularly for aggressive and refractory tumors where standard treatments fall short.
What we're watching
- Clinical Validation
- Whether the promising early data from the INVINCIBLE-4 study will translate into statistically significant results in larger patient populations.
- Funding Strategy
- The pace at which Intensity Therapeutics can secure additional funding to resume and complete its clinical trials, particularly the INVINCIBLE-3 study.
- Regulatory Pathway
- How the company navigates the regulatory landscape to bring INT230-6 to market, given the unique nature of its intratumoral delivery mechanism.
Related topics